Linked Life Data

16801478

Source:http://linkedlifedata.com/resource/pubmed/id/16801478

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2006-7-21
pubmed:abstractText
Drospirenone (DRSP), a progestin with antialdosterone activity, has been developed for hormone therapy in combination with 17-beta-estradiol (E2) in postmenopausal women. We evaluated the antihypertensive efficacy and safety of various doses of DRSP and E2 and estradiol alone in postmenopausal women with hypertension using ambulatory and clinic blood pressure (BP) monitoring. This was a randomized, double-blind clinical trial of 3 doses of DRSP combined with estradiol, estradiol alone, and placebo in 750 postmenopausal women with stage 1 to 2 hypertension between 45 to 75 years. Ambulatory and clinic BPs, potassium, aldosterone, and lipid measurements and adverse events were evaluated in postmenopausal women with stages 1 to 2 hypertension during 8 weeks of double-blind therapy. DRSP and E2 induced dose-related reductions in the ambulatory and clinic systolic BP with physiological increases in serum aldosterone. Significant decreases in 24-hour systolic pressure were observed at doses of 2 and 3 mg of DRSP combined with estradiol but not by estradiol alone or 1 mg of DRSP with estradiol. There were no significant changes from baseline in potassium in any treatment group. Small, significant reductions in total and low-density lipoprotein cholesterol occurred on all of the active treatments, and serum triglycerides did not change. Adverse event rates were low and similar across treatment groups. In conclusion, these data show that DRSP combined with E2 significantly reduces BP in postmenopausal women with hypertension and did not induce significant increases in serum potassium. These characteristics may lead to a new benefit for this novel hormone therapy in postmenopausal women with hypertension.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1524-4563
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
246-53
pubmed:dateRevised
2007-9-26
pubmed:meshHeading
pubmed-meshheading:16801478-Aged, pubmed-meshheading:16801478-Aldosterone, pubmed-meshheading:16801478-Androstenes, pubmed-meshheading:16801478-Blood Pressure, pubmed-meshheading:16801478-Blood Pressure Monitoring, Ambulatory, pubmed-meshheading:16801478-Cholesterol, pubmed-meshheading:16801478-Dose-Response Relationship, Drug, pubmed-meshheading:16801478-Double-Blind Method, pubmed-meshheading:16801478-Drug Therapy, Combination, pubmed-meshheading:16801478-Estradiol, pubmed-meshheading:16801478-Estrogen Replacement Therapy, pubmed-meshheading:16801478-Female, pubmed-meshheading:16801478-Heart Rate, pubmed-meshheading:16801478-Humans, pubmed-meshheading:16801478-Hypertension, pubmed-meshheading:16801478-Middle Aged, pubmed-meshheading:16801478-Postmenopause, pubmed-meshheading:16801478-Potassium, pubmed-meshheading:16801478-Treatment Outcome
pubmed:year
2006
pubmed:articleTitle
Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension.
pubmed:affiliation
Division of Hypertension and Clinical Pharmacology, The Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Ave, Farmington, CT 06030-3940, USA. wwhite@nso1.uchc.edu
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study